Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 0.78 |
| ▸ | THRB | P10828 | 3/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15748945 | 0.92 | MAPT (0.73) | MAPTTHRBALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL13977658 | 0.91 | MAPT (0.80) | MAPTTHRBALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL15748801 | 0.90 | MAPT (0.62) | MAPTTHRBALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL15748874 | 0.88 | MAPT (0.81) | MAPTTHRBALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL13977659 | 0.87 | MAPT (0.80) | MAPTTHRBALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL13977289 | 0.87 | MAPT (1.00) | MAPTTHRBALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL15502378 | 0.86 | MAPT (0.78) | MAPTTHRBALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL15748850 | 0.85 | MAPT (0.69) | MAPTTHRBALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL15748942 | 0.82 | MAPT (0.71) | MAPTTHRBALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL15748795 | 0.82 | MAPT (0.78) | MAPTTHRBALDH1A1MAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9676779-B2 | Small molecule CFTR correctors | DISCOVERYBIOMED, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-9676779-B2 | Small molecule CFTR correctors | DISCOVERYBIOMED, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-20150299206-A1 | SMALL MOLECULE CFTR CORRECTORS | DISCOVERYBIOMED, INC. (US) | 2015-10-22 | — | — | US | disclosed |
| US-20150299206-A1 | SMALL MOLECULE CFTR CORRECTORS | DISCOVERYBIOMED, INC. (US) | 2015-10-22 | — | — | US | disclosed |
| WO-2014081820-A1 | SMALL MOLECULE CFTR CORRECTORS | DISCOVERYBIOMED, INC. (US) | 2014-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150299206-A1 | SMALL MOLECULE CFTR CORRECTORS | CFTR, CLCN2, SLC26A4 | MAPT 4258/4885THRB 2036/4885ALDH1A1 3475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.